Prelude Capital Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Prelude Capital Management’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-10,550	Closed	-$1.08M	–	1459
2023 Q2	$1.08M	Buy	+10,550	New	+$998K	0.07%	297
2021 Q2	–	Sell	-10,050	Closed	-$1M	–	2068
2021 Q1	$1M	Buy	+10,050	New	+$1.17M	0.03%	602
2020 Q4	–	Sell	-7,652	Closed	-$745K	–	2157
2020 Q3	$745K	Buy	7,652 +7,267	+1,888%	+$908K	0.04%	335
2020 Q2	$60K	Buy	+385	New	+$58.5K	﹤0.01%	1119
2020 Q1	–	Sell	-19,423	Closed	-$3.97M	–	2175
2019 Q4	$3.97M	Sell	19,423 -34,453	-64%	-$6.29M	0.15%	88
2019 Q3	$4.33M	Buy	53,876 +11,182	+26%	+$949K	0.19%	63
2019 Q2	$4.03M	Buy	+42,694	New	+$3.69M	0.2%	78
2018 Q2	–	Sell	-12,412	Closed	-$255K	–	2020
2018 Q1	$255K	Buy	+12,412	New	+$319K	0.02%	627

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Prelude Capital Management's RETA Position: Q3 2023 in Review

Prelude Capital Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 10,550 shares — an estimated $1.08M sold.

Prelude Capital Management first reported a position in RETA in Q1 2018 and held it in 8 quarters. The position peaked at $4.33M in Q3 2019. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

Prelude Capital Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Prelude Capital Management sold 10,550 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $1.08M.
Prelude Capital Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2018 and held it in 8 quarters.
Prelude Capital Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $4.33M in Q3 2019.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Prelude Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.